98%
921
2 minutes
20
Background, Natural orifice specimen extraction (NOSE) via the anus or vagina is an alternative to conventional transabdominal specimen extraction in laparoscopic colorectal cancer surgery. NOSE has been shown to be safe and effective, resulting in decreased postoperative pain, analgesia use, and improved recovery, without oncological compromise. We aimed to demonstrate the feasibility of NOSE for combined colectomy with liver metastasectomy. Methods, From July 2022 to April 2024, all cases of laparoscopic colorectal cancer resection and synchronous liver metastasectomy with NOSE were included in the study. Selection criteria included a maximum specimen diameter of less than 5 cm and patient body mass index of less than 35 kg/m. Results, Over the 22-month duration, four consecutive patients (two males, two females) underwent combined resection with NOSE. Mean age and BMI were 74.8 (range 63-81) years and 20.9 (range 19.5-22.3) kg/m respectively. Patient A and D underwent anterior resection for sigmoid cancer, Patient B underwent D3 right hemicolectomy for cecal cancer, and Patient C underwent subtotal colectomy for synchronous cecal and descending colon cancer. All patients underwent liver metastasectomy at the same sitting. Patient A and D had transanal NOSE while Patients B and C underwent transvaginal NOSE. Mean operative time and blood loss was 416 (range 330-535) minutes and 338 (range 50-500) ml respectively. All patients recovered gastrointestinal function within the first two postoperative days. Infected seroma of the liver bed occurred in one patient requiring percutaneous drainage. The average maximum colon tumor diameter was 2.9 (range 1.3-4.0) cm. All resection margins were clear. Mean duration of follow-up was 7.5 (range 2-12) months. Conclusions, Simultaneous colectomy and liver metastasectomy with NOSE for colorectal cancer is feasible and safe in highly selected patients, resulting in good postoperative outcomes. This proof-of-concept analysis paves the way for larger studies to draw definitive conclusions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11252925 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2024.e33065 | DOI Listing |
J Urol
August 2025
Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Purpose: Patients with metastatic renal cell carcinoma (mRCC) with oligometastatic disease can achieve radiographic disease-free (M1 NED) status after cytoreductive nephrectomy and concurrent complete metastasectomy. This study aimed to evaluate outcomes and identify risk factors associated with metastatic recurrence and overall survival in patients with mRCC M1 NED.
Materials And Methods: Patients with synchronous mRCC who were M1 NED after cytoreductive nephrectomy and concurrent complete metastasectomy from 4 institutions (2010-2020) were identified.
Sci Rep
August 2025
Department of General Surgery, Division of Pancreatic Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, People's Republic of China.
Recent studies have considered pancreatectomy combined with synchronous metastasectomy as a potential treatment option for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate the role of surgery in PDAC patients with hepatic metastases and to identify the prognostic factors. PubMed, Embase, and Cochrane Library databases were searched and the hazard ratio (HR) with 95% confidence interval (CI) was extracted from eligible studies.
View Article and Find Full Text PDFMinerva Surg
August 2025
Unit of General Surgery, Vito Fazzi Hospital, Lecce, Italy.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer, with a 5-year survival of 8-10%. Approximately 50% of cases present with metastases at time of diagnosis, with the liver representing the most common site. International guidelines recommend palliative chemotherapy for metastatic disease, yet several studies report prolonged survival after surgery or locoregional therapy in selected patients with both synchronous and metachronous liver metastases (LM).
View Article and Find Full Text PDFBr J Cancer
July 2025
Department of Oncology, Addenbrooke's Hospital, Cambridge, UK.
Background: The histopathological growth patterns (HGPs) of colorectal cancer liver metastases broadly classify patients into two groups post-liver metastasectomy, with encapsulated HGP indicating a more favourable prognosis. The potential association between HGPs and specific mutations is poorly understood.
Methods: Using next-generation sequencing data of 461 resected patients (104 patients with encapsulated versus 357 patients with non-encapsulated HGP), 19 putative colorectal cancer driver genes, tumour mutational burden (TMB), and microsatellite instability (MSI) or POLE mediated hypermutation were compared.
Clin Exp Metastasis
July 2025
Department of Oncology, Stavanger University Hospital, Stavanger, Norway.
Metastatic cancer has been considered uniformly fatal in the past with very poor outcomes for most cancer sites. However, novel systemic and targeted therapies have rendered unique responses with longer survival across several cancer types and metastatic sites. In addition, improved surgical experience and safety with good outcomes has made metastasectomy as an alternative curative-intent treatment across multiple organ sites.
View Article and Find Full Text PDF